Abatacept biosimilar is under clinical development by Dr. Reddy’s Laboratories and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Abatacept biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abatacept biosimilar overview
Abatacept biosimilar (DRL_AB) is under development for the treatment of rheumatoid arthritis. The therapeutic candidate acts by targeting CD80 and CD86 and is administered through subcutaneous route.
Dr. Reddy’s Laboratories overview
Dr. Reddy’s Laboratories (Dr. Reddy’s), is an integrated global pharmaceutical company. The company’s primary activities include the manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products, active pharmaceutical ingredients (API), and intermediates. The company offers a range of products including generics, branded generics, biosimilars, and over-the-counter pharmaceutical products. The company’s products are used in various medical fields such as gastroenterology, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s serves customers worldwide, providing access to affordable and innovative medicines. Its pipeline includes New Chemical Entities (NCEs) that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation. The company markets products in the US, Europe, Latin America, and Asia. Dr. Reddy’s is headquartered in Hyderabad, Telangana, India
For a complete picture of Abatacept biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
